Abstract
The workshop Rift Valley Fever Vaccine Development, Progress and Constraints was organized by the Food and Agriculture Organization of the United Nations (FAO) and the Central Veterinary Institute of Wageningen University and Research Centre, under the umbrella of the Global Framework for the Progressive Control of Transboundary Animal Diseases, a joint initiative of FAO and the World Organisation for Animal Health. The workshop was supported by the Netherlands Ministry of Economic Affairs, Agriculture and Innovation, and by the US Centers for Disease Control and Prevention; other participants included the World Health Organization and the International Atomic Energy Agency. The meeting occurred January 19–21, 2011, at FAO headquarters in Rome, Italy, and was attended by 34 leading scientists in Rift Valley fever virus (RVFV) vaccine development, representatives of international organizations, and policy makers. Stakeholders from industry were represented by the International Federation for Animal Health. The main objective of the meeting was to gain consensus about desired characteristics of novel veterinary RVFV vaccines and to discuss how incentives can be established to ensure that these vaccines come to market.
Highlights
The workshop Rift Valley Fever Vaccine Development, Progress and Constraints was organized by the Food and Agriculture Organization of the United Nations (FAO) and the Central Veterinary Institute of Wageningen University and Research Centre, under the umbrella of the Global Framework for the Progressive Control of Transboundary Animal http://wwwnc.cdc.gov/eid/article/17/9/11-0506_article.htm[13-1-2012 11:17:22]
The main objective of the meeting was to gain consensus about desired characteristics of novel veterinary Rift Valley fever virus (RVFV) vaccines and to discuss how incentives can be established to ensure that these vaccines come to market
A safe alternative is based on inactivated whole virus. This vaccine requires a booster and annual revaccination. Drawbacks of these classical vaccines explain the need for a new generation of RVFV vaccines
Summary
Jeroen Kortekaas (/eid/article/17/9/110506_article.htm#comment) , James Zingeser, Peter de Leeuw, Stephane de La Rocque, Hermann Unger, and Rob J.M. The workshop Rift Valley Fever Vaccine Development, Progress and Constraints was organized by the Food and Agriculture Organization of the United Nations (FAO) and the Central Veterinary Institute of Wageningen University and Research Centre, under the umbrella of the Global Framework for the Progressive Control of Transboundary Animal http://wwwnc.cdc.gov/eid/article/17/9/11-0506_article.htm[13-1-2012 11:17:22]. VLPs that express the nucleocapsid gene from a packaged minigenome were produced and provided complete protection in mice after a single vaccination (19 (#r19) ) These results, together with recently established improved production methods, suggest that VLP-based vaccines can soon become cost-effective alternatives for live vaccines. At the end of the workshop, participants drafted 11 recommendations to guide and facilitate the development of RVFV vaccines, norms and standards, and vaccine stockpiles for rapid deployment These recommendations and other meeting documents are available at www.fao.org/ag/againfo/programmes/en/empres/RVF
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
